公开资料显示，微创医疗科学有限公司起源于1998年5月在上海张江高科技园区成立的微创医疗器械（上海）有限公司，为中国领先的高端医疗器械集团。目前“微创系”共有6家上市公司，分别是母公司微创医疗，以及心脉医疗、心通医疗、微创机器人、微创脑科学、微电生理5家子公司。据悉，公司2021年6月发行的7亿美元可转债于2024年6月可被投资人要求赎回，公司自2023年底起采取多种途径筹资，包括发行新可转债、可换股定期贷款融资、获取金融机构信贷支持等方式，短期流动性风险已得到化解。Minimally Invasive was higher across the board. As of press release, MEDBOT-B (02252) rose 26.05% to HK$11.66; Minimally Invasive Medicine (00853) rose 11.6% to HK$6.83; Minimally Invasive Brain Science (02172) rose 9.14% to HK$9.79; and CARDIOFLOW-B (02160) rose 2.86% to HK$0.72.
The Zhitong Finance App learned that minimally invasive was higher across the board. As of press release, MEDBOT-B (02252) rose 26.05% to HK$11.66; minimally invasive medicine (00853) rose 11.6% to HK$6.83; minimally invasive brain science (02172) rose 9.14% to HK$9.79; and CARDIOFLOW-B (02160) rose 2.86% to HK$0.72.
According to the news, Shanghai issued the “Shanghai Action Plan to Support Mergers, Acquisitions and Restructuring of Listed Companies (2025-2027)”. The plan proposes to introduce market-based M&A fund managers on a professional circuit, attract market-based M&A funds, and establish a fast track for eligible equity investment funds. Make good use of the 10 billion yuan integrated circuit design industry merger and acquisition fund and establish a 10 billion yuan biomedical industry merger and acquisition fund. Furthermore, in July, Shanghai issued “Certain Opinions on Supporting the Innovation and Development of the Whole Chain of the Biomedical Industry”, which proposed the establishment of the Shanghai Biomedical Industry M&A Fund to actively guide biomedical enterprises in a position to do so to initiate the establishment of mergers and acquisitions funds in accordance with the needs of industrial transformation and upgrading, and to support enterprises to carry out mergers and acquisitions investment upstream and downstream of the industrial chain.
According to public information, Minimally Invasive Medical Science Co., Ltd. originated from Minimally Invasive Medical Devices (Shanghai) Co., Ltd. established in Shanghai's Zhangjiang Hi-Tech Park in May 1998, and is a leading high-end medical device group in China. Currently, there are 6 listed companies in the “Minimally Invasive Department”, namely the parent company Minimally Invasive Healthcare, and 5 subsidiaries of Cardiovascular Medicine, Minimally Invasive Robotics, Minimally Invasive Brain Science, and Microelectrophysiology. According to reports, the 0.7 billion dollar convertible bonds issued by the company in June 2021 can be redeemed by investors in June 2024. Since the end of 2023, the company has used various methods to raise capital, including issuing new convertible bonds, financing convertible term loans, and obtaining credit support from financial institutions. Short-term liquidity risks have been mitigated.
Comment(0)
Reason For Report